Odefsey® (emtricitabine/rilpivirine/tenofovir alafenamide) – Expanded indication
February 19, 2025 - The FDA approved Gilead’s Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide), as a complete regimen for the treatment of HIV-1 infection in adult and pediatric patients weighing at least 25 kg as initial therapy in those with no antiretroviral treatment history with HIV-1 RNA less than or equal to 100,000 copies/mL or to replace a stable antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies/mL) for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Odefsey.
Top